$13.57
-0.05 (-0.37%)
Open$13.69
Previous Close$13.62
Day High$14.23
Day Low$13.12
52W High$18.57
52W Low$7.48
Volume—
Avg Volume3.91M
Market Cap2.04B
P/E Ratio—
EPS$-5.67
SectorBiotechnology
Analyst Ratings
Strong Buy
25 analysts
Price Target
+121.5% upside
Current
$13.57
$13.57
Target
$30.06
$30.06
$17.22
$30.06 avg
$35.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 166.56M | 159.79M | 165.80M |
| Net Income | 26.40M | 27.52M | 28.79M |
| Profit Margin | 15.9% | 17.2% | 17.4% |
| EBITDA | 53.49M | 47.96M | 56.14M |
| Free Cash Flow | 17.32M | 22.87M | 17.57M |
| Rev Growth | +0.5% | -2.4% | +23.6% |
| Debt/Equity | 0.62 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |